Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.
Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén, Joacim Malmqvist and Rebecka Björnestedt.
